PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25344740-6 2014 Either pharmacological reconstitution of FoxO1 activity using intravenous or inhaled paclitaxel, or reconstitution of the transcriptional activity of FoxO1 by gene therapy, restored the physiologically quiescent PASMC phenotype in vitro, linked to changes in cell cycle control and bone morphogenic protein receptor type 2 (BMPR2) signaling, and reversed vascular remodeling and right-heart hypertrophy in vivo. pasmc 212-217 bone morphogenetic protein receptor type 2 Homo sapiens 282-322 25344740-6 2014 Either pharmacological reconstitution of FoxO1 activity using intravenous or inhaled paclitaxel, or reconstitution of the transcriptional activity of FoxO1 by gene therapy, restored the physiologically quiescent PASMC phenotype in vitro, linked to changes in cell cycle control and bone morphogenic protein receptor type 2 (BMPR2) signaling, and reversed vascular remodeling and right-heart hypertrophy in vivo. pasmc 212-217 bone morphogenetic protein receptor type 2 Homo sapiens 324-329 23525442-6 2013 As RAGE is one of the most upregulated proteins in PAH patients" lungs and a strong STAT3 activator, we hypothesized that by activating STAT3, RAGE induces BMPR2 and PPARgamma downregulation, promoting PAH-PASMC proliferation and resistance to apoptosis. pasmc 206-211 bone morphogenetic protein receptor type 2 Homo sapiens 156-161 22688668-10 2013 In sum, these results indicate that generally both receptors are reduced in PAH particularly ETB, and that ETB signaling through protein kinases becomes markedly reduced in BMPR2 PASMC, while it continues in IPAH. pasmc 179-184 bone morphogenetic protein receptor type 2 Homo sapiens 173-178 17142350-2 2007 Decreased BMPR2 expression and impaired intracellular BMP signaling in pulmonary artery (PA) smooth muscle cells (PASMC) suppresses apoptosis and promotes proliferation, thereby contributing to the pathogenesis of PAH. pasmc 114-119 bone morphogenetic protein receptor type 2 Homo sapiens 10-15 22718766-4 2012 Here we report the BMPR2-dependent repression of a set of inflammatory mediators in response to BMP4 stimulation of PASMC. pasmc 116-121 bone morphogenetic protein receptor type 2 Homo sapiens 19-24 30453304-10 2018 CONCLUSION: Our study indicates that SphK1/S1P pathway plays an important role in PDGF-induced PASMC proliferation via miR-21/BMPRII/Id1 axis and targeting against SphK1/S1P axis might be a novel strategy in the prevention and treatment of pulmonary arterial hypertension (PAH). pasmc 95-100 bone morphogenetic protein receptor type 2 Homo sapiens 126-132 28828907-6 2017 PASMC have reduced inflammatory activation in response to IL-1ss compared with AoSMCs; however, PASMC with reduced BMPR2 demonstrated an exaggerated response. pasmc 96-101 bone morphogenetic protein receptor type 2 Homo sapiens 115-120 28187784-16 2017 CONCLUSIONS: Collectively, this study suggests that MSCs modified with let-7a may ameliorate the progression of PAH by inhibiting PASMC growth through the STAT3-BMPR2 signaling, supporting a promising therapeutic strategy for PAH patients. pasmc 130-135 bone morphogenetic protein receptor type 2 Homo sapiens 161-166 28084316-4 2017 TNFalpha-mediated suppression of BMPR-II subverts BMP signalling, leading to BMP6-mediated PASMC proliferation via preferential activation of an ALK2/ACTR-IIA signalling axis. pasmc 91-96 bone morphogenetic protein receptor type 2 Homo sapiens 33-40 27816994-7 2016 PMECs from BMPR2 mutation carriers induced an increase in PASMC mitogenic activity; moreover, endothelin-1 secretion by PMECs from carriers was higher than by PMECs from non-carriers. pasmc 58-63 bone morphogenetic protein receptor type 2 Homo sapiens 11-16